Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).

Orphanet journal of rare diseases - 24 Apr 2015

Pano Arian, Barbier Ann J, Bielefeld Bonnie, Whiteman David A H, Amato David A

Abstract excerpt

BACKGROUND: Twenty-eight treatment-naïve mucopolysaccharidosis II patients (16 months-7.5 years) received 0.5 mg/kg idursulfase weekly for one year in NCT00607386. Serum anti-idursulfase immunoglobulin G antibodies (Abs) were seen in 68% of patients. METHODS: This post hoc analysis examined the r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Replacement Therapy
Share to Iduronate Sulfatase
Share to Immunoglobulin G

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mucopolysaccharidosis II

Share to Organ Size

Share to Spleen

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25902842
DOI: 10.1186/s13023-015-0265-2
PMCID: PMC4416269

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25902842-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).PMID 25902842Read ↗

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.Semantic proximity Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.Semantic proximity Read ↗

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?Semantic proximity Read ↗

A Review Of The Clinical Outcomes In Idursulfase-Treated And Untreated Filipino Patients With Mucopolysaccharidosis Type II: Data From The Local Lysosomal Storage Disease RegistrySemantic proximity Read ↗

A molecular genetics view on Mucopolysaccharidosis Type II.Semantic proximity Read ↗

Identification of 6 new mutations in the iduronate sulfatase gene. Mutation in brief no. 233. Online.Semantic proximity Read ↗

Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).Semantic proximity Read ↗

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.Semantic proximity Read ↗

Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapySemantic proximity Read ↗

A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type ISemantic proximity Read ↗

First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BSemantic proximity Read ↗

Genotype-phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.